TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$53.31
-0.21 (-0.39%)
▼
5d:
-0.6%
30d:
+45.5%
90d:
+58.76%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 03, 2026
30d
Smart Money Accumulation
None View Scanner →
Strength: 6.2/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TGTX shows positive signals but monitor for confirmation. Market pricing in 6.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TGTX shows positive signals but monitor for confirmation. Market pricing in 6.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$86.69
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$53.83
1.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $53.31, which is considered slightly high relative to its 30-day fair value range of $40.43 to $53.91. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.6) compared to its historical average (15.5). At these levels, the market is pricing in 6.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $51.15, while resistance sits at $57.38.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $51.15, while resistance sits at $57.38.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$40.43 -
$53.91
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($51.71)
- NEUTRAL: PE elevated vs history but 6.2% growth expectation is conservative given 300% recent growth
Trading Range Analysis
30-Day Trading Range
$40.43 -
$53.91
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$51.15
Resistance Level
$57.38
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.56
Wall Street Target
$51.71
(-3.0%)
Revenue Growth (YoY)
69.6%
Earnings Growth (YoY)
300.0%
Profit Margin
66.0%
Valuation Premium vs History
+6.2% premium
PE vs Historical
18.6 vs 15.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.2%
(market-implied from PE analysis)
1-Year Target
$56.62
(+6%)
2-Year Target
$60.13
(+13%)
3-Year Target
$63.85
(+20%)
3-Yr Target (if PE normalizes)
(PE: 19→16)
PE COMPRESSION
$53.32
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 87.1%)
$211.13
(+296%)
Base:
(SPY PE: 18.6, Growth: 87.1%)
$179.92
(+238%)
Bear:
(PE: 15.5, Growth: 87.1%)
$150.25
(+182%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 18.71 | Current EPS (TTM): $2.86
Bull Case
$59.12
(+11%)
Analyst growth 0.4%, PE expands to 20.6
Base Case
$53.75
(+1%)
Market implied 0.4%, PE stable at 18.7
Bear Case
$36.39
(-32%)
Severe decline -20.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 6:10 PM ET
Data refreshes hourly during market hours. Next update: 7:10 PM
Data refreshes hourly during market hours. Next update: 7:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
